← Leaderboards

Dean W Felsher

Stanford University

Google Scholar ↗PubMed ↗ORCID ↗

$32,145,773

Attributed

$50,197,936

Total exposure

17

Grants

14

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $11.6M · FY2005–25

$20M$15M$10M$5M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$50,197,936 · 17

By mechanism

UM1$20,074,946 · 1

R01$12,629,979 · 5

R35$5,894,176 · 1

U01$4,556,381 · 2

T32$1,769,428 · 1

P01$1,720,453 · 1

Top collaborators

Most similar at Stanford University

Same institution · by research overlap

M Bishr Omary$19,144,528
Sylvia Katina Plevritis$44,733,712
Richard N Zare$3,249,968
Beth Denise Darnall$2,799,865
Sean C Mackey$29,867,463

Others in their field

Top investigators on “Malignant Neoplasms”

David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
Richard K. Wilson · Washington University$274,272,747
Larry Arthur$223,443,122
Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879

Research focus

Malignant NeoplasmsProgramsTumorOncogenesCellsTumorigenesisTransgenic MiceNeoplastic CellResearch PersonnelMediatingIn VivoMouse ModelApoptosisImmuneCancer TherapyGenesMolecularGeneticInsightExhibitsLymphomaResponsePathway InteractionsPrimary Carcinoma Of The Liver Cells

Grant awards (83)

Stanford Center for Clinical and Translational Research and Education$10,023,873

UM1 · FY2025 · TR

Targeting the MYC Pathway for the Treatment of Cancer$965,767

R35 · FY2025 · CA · contact PI

Molecular Mechanisms by which Statins Prevent and Reverse Hepatocellular Carcinoma$656,499

U01 · FY2025 · CA · contact PI

Stanford Center for Clinical and Translational Research and Education$10,051,073

UM1 · FY2024 · TR

Targeting the MYC Pathway for the Treatment of Cancer$916,896

R35 · FY2024 · CA · contact PI

Molecular Mechanisms by which Statins Prevent and Reverse Hepatocellular Carcinoma$311,876

U01 · FY2024 · CA · contact PI

Targeting the MYC Pathway for the Treatment of Cancer$122,033

R35 · FY2024 · CA · contact PI

Targeting the MYC Pathway for the Treatment of Cancer$73,613

R35 · FY2024 · CA · contact PI

Targeting the MYC Pathway for the Treatment of Cancer$945,225

R35 · FY2023 · CA · contact PI

Molecular Mechanisms by which Statins Prevent and Reverse Hepatocellular Carcinoma$341,920

U01 · FY2023 · CA · contact PI

Targeting the MYC Pathway for the Treatment of Cancer$944,622

R35 · FY2022 · CA · contact PI

Targeting the MYC Pathway for the Treatment of Cancer$963,300

R35 · FY2021 · CA · contact PI

Targeting the MYC Pathway for the Treatment of Cancer$962,720

R35 · FY2020 · CA · contact PI

(PQ7)Multi-scale Analysis of Tumor Microenvironment Heterogeneity$708,822

R01 · FY2019 · CA · contact PI

Cancer-Translational Nanotechnology Training Program (Cancer-TNT)$405,557

T32 · FY2019 · CA

(PQ7)Multi-scale Analysis of Tumor Microenvironment Heterogeneity$730,063

R01 · FY2018 · CA · contact PI

Modeling and Predicting Therapeutic Resistance of Cancer$605,631

U01 · FY2018 · CA · contact PI

Prognostic Metabolic Signatures of Cancers Through Mass Spectrometry Imaging$528,101

R01 · FY2018 · CA · contact PI

Cancer-Translational Nanotechnology Training Program (Cancer-TNT)$388,196

T32 · FY2018 · CA

(PQ7)Multi-scale Analysis of Tumor Microenvironment Heterogeneity$729,393

R01 · FY2017 · CA · contact PI

Modeling and Predicting Therapeutic Resistance of Cancer$614,898

U01 · FY2017 · CA · contact PI

Prognostic Metabolic Signatures of Cancers Through Mass Spectrometry Imaging$528,101

R01 · FY2017 · CA · contact PI

Cancer-Translational Nanotechnology Training Program (Cancer-TNT)$374,272

T32 · FY2017 · CA

Modeling and Predicting Therapeutic Resistance of Cancer$85,604

U01 · FY2017 · CA · contact PI

Cancer-Translational Nanotechnology Training Program (Cancer-TNT)$7,697

T32 · FY2017 · CA

Cancer-Translational Nanotechnology Training Program (Cancer-TNT)$6,346

T32 · FY2017 · CA

Modeling and Predicting Therapeutic Resistance of Cancer$614,775

U01 · FY2016 · CA · contact PI

Prognostic Metabolic Signatures of Cancers Through Mass Spectrometry Imaging$528,101

R01 · FY2016 · CA · contact PI

Cancer-Translational Nanotechnology Training Program (Cancer-TNT)$360,353

T32 · FY2016 · CA

Modeling and Predicting Therapeutic Resistance of Cancer$87,920

U01 · FY2016 · CA · contact PI

Modeling and Predicting Therapeutic Resistance of Cancer$614,899

U01 · FY2015 · CA · contact PI

Prognostic Metabolic Signatures of Cancers Through Mass Spectrometry Imaging$528,101

R01 · FY2015 · CA · contact PI

Mechanisms by which Oncogene Inactivation Elicits Tumor Cell Death$525,337

R01 · FY2015 · CA · contact PI

Cancer-Translational Nanotechnology Training Program (Cancer-TNT)$227,007

T32 · FY2015 · CA

Modeling and Predicting Therapeutic Resistance of Cancer$622,359

U01 · FY2014 · CA · contact PI

Prognostic Metabolic Signatures of Cancers Through Mass Spectrometry Imaging$569,601

R01 · FY2014 · CA · contact PI

Mechanisms by which Oncogene Inactivation Elicits Tumor Cell Death$509,576

R01 · FY2014 · CA · contact PI

Multi-Modality Imaging of Oncogene Addiction$144,404

P50 · FY2014 · CA · contact PI

MODELING THE ROLE OF DIFFERENTIATION IN T-ALL$132,314

U54 · FY2014 · CA · contact PI

Mechanisms by which Oncogene Inactivation Elicits Tumor Cell Death$512,190

R01 · FY2013 · CA · contact PI

MODELING THE ROLE OF DIFFERENTIATION IN T-ALL$154,358

U54 · FY2013 · CA · contact PI

Nanoscale proteomic profiles of hypoxia pathways to develop biomarkers of renal c$148,519

R21 · FY2013 · CA · contact PI

Multi-Modality Imaging of Oncogene Addiction$135,714

P50 · FY2013 · CA · contact PI

Mechanisms by which Oncogene Inactivation Elicits Tumor Cell Death$544,883

R01 · FY2012 · CA · contact PI

Nanoscale proteomic profiles of hypoxia pathways to develop biomarkers of renal c$181,399

R21 · FY2012 · CA · contact PI

MODELING THE ROLE OF DIFFERENTIATION IN T-ALL$178,866

U54 · FY2012 · CA · contact PI

Multi-Modality Imaging of Oncogene Addiction$109,905

P50 · FY2012 · CA · contact PI

MYC's Role in the Initiation and Maintenance of Cancer$387,426

R01 · FY2011 · CA · contact PI

MODELING THE ROLE OF DIFFERENTIATION IN T-ALL$171,867

U54 · FY2011 · CA · contact PI

Multi-Modality Imaging of Oncogene Addiction$123,005

P50 · FY2011 · CA · contact PI

MYC's Role in the Initiation and Maintenance of Cancer$399,339

R01 · FY2010 · CA · contact PI

Immune Status and Tumor Regression Upon Oncogene Inactivation$384,832

P01 · FY2010 · CA · contact PI

Molecular and Cellular Basis of Oncogene Addiction$328,804

R01 · FY2010 · CA · contact PI

MODELING THE ROLE OF DIFFERENTIATION IN T-ALL$187,343

U54 · FY2010 · CA · contact PI

Multi-Modality Imaging of Oncogene Addiction$147,124

P50 · FY2010 · CA · contact PI

MYC's Role in the Initiation and Maintenance of Cancer$391,431

R01 · FY2009 · CA · contact PI

Immune Status and Tumor Regression Upon Oncogene Inactivation$377,520

P01 · FY2009 · CA · contact PI

Molecular and Cellular Basis of Oncogene Addiction$328,140

R01 · FY2009 · CA · contact PI

Multi-Modality Imaging of Oncogene Induced Tumorigenesis$223,727

P50 · FY2009 · CA · contact PI

Firefly Shared Instrument Grant$433,000

S10 · FY2008 · RR · contact PI

MYC's Role in the Initiation and Maintenance of Cancer$379,965

R01 · FY2008 · CA · contact PI

Immune Status and Tumor Regression Upon Oncogene Inactivation$365,645

P01 · FY2008 · CA · contact PI

Multi-Modality Imaging of Oncogene Induced Tumorigenesis$226,103

P50 · FY2008 · CA · contact PI

MYC's Role in the Initiation and Maintenance of Cancer$375,138

R01 · FY2007 · CA · contact PI

Immune Status and Tumor Regression Upon Oncogene Inactivation$363,383

P01 · FY2007 · CA · contact PI

Differentiation of Osteogenic Sarcoma by MYC$316,462

R01 · FY2007 · CA · contact PI

Multi-Modality Imaging of Oncogene Induced Tumorigenesis$230,639

P50 · FY2007 · CA · contact PI

Differentiation of Osteogenic Sarcoma by MYC$325,696

R01 · FY2006 · CA · contact PI

Immune Status and Tumor Regression Oncogene Inactivation$229,073

P01 · FY2006 · CA · contact PI

Multi-Modality Imaging of Oncogene-Induced Tumor$145,715

P50 · FY2006 · CA · contact PI

MYC's Role in the Initiation and Maintenance of Cancer$39,000

R01 · FY2006 · CA · contact PI

MYC's Role in the Initiation and Maintenance of Cancer$366,565

R01 · FY2005 · CA

Differentiation of Osteogenic Sarcoma by MYC$333,321

R01 · FY2005 · CA

Multi-Modality Imaging of Oncogene-Induced Tumor$145,715

P50 · FY2005 · CA

MYC's Role in the Initiation and Maintenance of Cancer$355,890

R01 · FY2004 · CA

Differentiation of Osteogenic Sarcoma by MYC$333,112

R01 · FY2004 · CA

MYC's Role in the Initiation and Maintenance of Cancer$364,704

R01 · FY2003 · CA

MYC's Role in the Initiation and Maintenance of Cancer$100,000

R01 · FY2003 · CA

MYC's Role in the Initiation and Maintenance of Cancer$233,044

R01 · FY2002 · CA

C-MYC INDUCED TUMORIGENESIS AND GENOMIC INSTABILITY$122,121

K08 · FY2002 · CA

MYC's Role in the Initiation and Maintenance of Cancer$329,673

R01 · FY2001 · CA

C-MYC INDUCED TUMORIGENESIS AND GENOMIC INSTABILITY$122,121

K08 · FY2001 · CA

C-MYC INDUCED TUMORIGENESIS AND GENOMIC INSTABILITY$88,614

K08 · FY2000 · CA